如何治疗EGFR突变非小细胞肺癌
Neel Belani1, Katherine Liang2, Michael Fradley3
1Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
奥西默提尼布是EGFR突变NSCLC的关键治疗方法. 这项研究表明,奥西默蒂尼布诱导的心肌病症可以安全管理,使患者能够从再挑战疗法中受益.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 表皮生长因子受体 (EGFR) 突变在非小细胞肺癌 (NSCLC),特别是腺癌中很常见.
- 奥西默提尼布是转移性NSCLC的第一线向疗法,具有特定的EGFR突变 (前列体19缺失,前列体21L858R).
- 虽然Osimertinib是有效的,但可能会导致皮疹,腹和严重的心脏问题,包括心肌病和QT间隔延长等副作用.
研究的目的:
- 评估Osimertinib诱导心肌病的治疗方法和结果.
- 评估在治疗心脏副作用后,重新使用奥西默蒂尼布的患者的安全性和疗效.
主要方法:
- 以后回顾的案例审查.
- 临床管理Osimertinib诱导的心肌病.
- 在Osimertinib重试期间对患者结果的监测.
主要成果:
- 奥西默提尼布诱导的心肌病症通过药物戒断和指导方针导向的医疗治疗成功管理.
- 重新接受奥西默提尼布治疗的患者表明,益处超过风险.
- 该病例系列表明,安全地重新使用奥西默提尼布是可行的.
结论:
- 奥西默提尼布诱导的心肌病是NSCLC患者可管理的副作用.
- 在控制心脏毒性后,重新使用奥西默提尼布可以是一个安全和有益的治疗策略.
- 这种方法允许在Osimertinib是最佳选择时继续使用有效疗法治疗.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
